- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03898986
The Effects of Attenuated Versus Inactivated Flu Vaccine in Twin Sets (FLU-TW)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is a Phase I mechanistic study of licensed influenza vaccines. The study requires 10 monozygotic and 10 dizygotic sets of twins (40 total participants) to enroll.
The duration of the study for an individual volunteer will be 4 weeks including screening and active participation. The study has a total of 3 visits.
First visit: Procedures during this visit are: Informed consent process, enrollment, study assessments, 20 ml blood draw, and vaccination. Participants will be randomized to receive either LAIV or IIV.
The time required to complete the first study visit will be about 30-40 minutes.
2nd (day 7 post vaccination) and 3rd (day 28 post vaccination ) visit: 20 ml blood will be obtained and the visit will take approximately 15 minutes.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Contact
- Name: Philip Grant
- Phone Number: 6507239443
- Email: pmgrant@stanford.edu
Study Locations
-
-
California
-
Stanford, California, United States, 94305
- Stanford University School of Medicine
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- 2-20 year old male and female patients
- Willing and able to complete the informed consent process
- Availability of twin pair also agreeable and eligible for study inclusion
- Availability for follow-up for the planned duration of the study
- Acceptable medical history by review of inclusion/exclusion criteria
Exclusion Criteria:
- Prior off-study vaccination with seasonal influenza vaccine within three months of study vaccination
- Life-threatening reactions to previous influenza vaccinations
- Asthma (contraindication for receipt of LAIV4)
- Allergy to egg or egg products or to vaccine components including gentamicin, gelatin, arginine or MSG.
- Active systemic or serious concurrent illness, including febrile illness on the day of vaccination
- History of immunodeficiency (including HIV infection)
- Known or suspected impairment of immunologic function; may include significant liver disease, diabetes mellitus treated with insulin or moderate to severe renal disease
- Hospitalization in the past year for congestive heart failure or emphysema.
- Chronic Hepatitis B or C.
- Recent or current use of immunosuppressive medication, including systemic glucocorticoids (corticosteroid nasal sprays and topical steroids are permissible). Use of oral steroids (<20mg prednisone-equivalent/day) may be acceptable after review by the investigator.
- Participants in close contact with anyone who has a severely weakened immune system
- Malignancy, other than squamous cell or basal cell skin cancer (includes solid tumors such as breast cancer or prostate cancer with recurrence in the past year, and any hematologic cancer such as leukemia).
- Autoimmune disease (including rheumatoid arthritis treated with immunosuppressive medication such as Plaquenil, methotrexate, prednisone, Enbrel) which, in the opinion of the investigator might jeopardize volunteer safety or compliance with the protocol.
- History of blood dyscrasias, renal disease, or hemoglobinopathies requiring regular medical follow up or hospitalization during the preceding year
- Use of any anti-coagulation medication such as Coumadin or Lovenox, or anti-platelet agents such as aspirin (except up to 325 mg. per day), Plavix, or Aggrenox will be reviewed by investigators to determine if study participation would affect the volunteer's safety or compliance with the protocol.
- Has taken an influenza antiviral medication within 48 hours prior to study vaccination [If yes, may not eligible if unable to schedule at an appropriate interval].
- Receipt of blood or blood products within the past 6 months or planned used during the study.
- Medical or psychiatric condition or occupational responsibilities that preclude participant compliance with the protocol
- Receipt of an inactivated vaccine 14 days prior to study enrollment, or planned vaccinations prior to completion of last study visit (~ 14 days after study vaccination)
- Receipt of a live, attenuated vaccine within 60 days prior to enrollment of planned vaccination prior to completion of last study visit (~ 14 days after study enrollment)
- Need for allergy immunization (that cannot be postponed) until after the last study visit.
- History of Guillain-Barre# syndrome
- Pregnant woman
- Breastfeeding woman
- Use of investigational agents within 30 days prior to enrollment or planned use during the study.
- Donation of the equivalent of a unit of blood within 6 weeks prior to enrollment or donation of platelets within 2 weeks of enrollment or planned donation prior to completion of the last visit.
- Any condition which, in the opinion of the investigator, might interfere with volunteer safety, study objectives or the ability of the participant to understand or comply with the study protocol.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: MZ twins (IIV or LAIV4)
Up to 20 healthy monozygotic (MZ) individual twin volunteers, 2-20 years old, will be randomized within the twin pair to receive either inactivated influenza vaccine quadrivalent (IIV4) Fluzone® Quadrivalent vaccine or live, attenuated influenza vaccine quadrivalent (LAIV4) FluMist® Quadrivalent.
Each volunteer will complete a total of 3 visits: Day 0 (pre-immunization), Day 7 and Day 28 post-immunization.
All visits will consist of drawing blood for study assays and monitoring for serious adverse events (SAEs).
|
LAIV4 vaccine dosage is 0.2 mL.
The vaccine will be administered as an intranasal spray.
Each sprayer contains a single dose of FluMist® Quadrivalent; approximately one-half of the contents should be administered into each nostril.
0.1 mL (i.e., half of the dose from a single FluMist sprayer) is administered into each nostril while the recipient is in an upright position.
Insert the tip of the sprayer just inside the nose and rapidly depress the plunger until the dose-divider clip stops the plunger.
The dose-divider clip is removed from the sprayer to administer the second half of the dose (0.1 mL) into the other nostril.
Other Names:
IIV4 vaccine will be administered as a 0.5 mL dose, with a sterile, disposable syringe and needle by IM injection.
Other Names:
|
Experimental: DZ twins (IIV or LAIV4)
Up to 20 healthy monozygotic (MZ) individual twin volunteers, 2-20 years old, will be randomized within the twin pair to receive either inactivated influenza vaccine quadrivalent (IIV4) Fluzone® Quadrivalent vaccine or live, attenuated influenza vaccine quadrivalent (LAIV4) FluMist® Quadrivalent.
Each volunteer will complete a total of 3 visits: Day 0 (pre-immunization), Day 7 and Day 28 post-immunization.
All visits will consist of drawing blood for study assays and monitoring for serious adverse events (SAEs).
|
LAIV4 vaccine dosage is 0.2 mL.
The vaccine will be administered as an intranasal spray.
Each sprayer contains a single dose of FluMist® Quadrivalent; approximately one-half of the contents should be administered into each nostril.
0.1 mL (i.e., half of the dose from a single FluMist sprayer) is administered into each nostril while the recipient is in an upright position.
Insert the tip of the sprayer just inside the nose and rapidly depress the plunger until the dose-divider clip stops the plunger.
The dose-divider clip is removed from the sprayer to administer the second half of the dose (0.1 mL) into the other nostril.
Other Names:
IIV4 vaccine will be administered as a 0.5 mL dose, with a sterile, disposable syringe and needle by IM injection.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
HAI titers
Time Frame: Day 0 to Day 28
|
Evaluate HAI titers in response to influenza vaccination.
|
Day 0 to Day 28
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Philip M Grant, Assistant Professor of Medicine (Infectious Diseases)
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 50200
- 5U19AI057229-15 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Influenza
-
Novartis VaccinesCompletedInfluenza | Seasonal Influenza | Human Influenza | Influenza Due to Unspecified Influenza VirusBelgium
-
Gamaleya Research Institute of Epidemiology and...CompletedInfluenza A | Influenza A Virus Infection | Influenza Epidemic | Influenza H5N1Russian Federation
-
Vanderbilt University Medical CenterHuman Vaccines ProjectCompletedVaccine Reaction | Influenza | Influenza, Human | Influenza A | Influenza Type B | Influenza A H3N2 | Influenza A H1N1United States
-
National Institute of Allergy and Infectious Diseases...Completed
-
National Institute of Allergy and Infectious Diseases...Completed
-
National Institute of Allergy and Infectious Diseases...CompletedInfluenza Immunisation | Avian InfluenzaUnited States
-
National Institute of Allergy and Infectious Diseases...CompletedInfluenza | Influenza Immunisation | Avian InfluenzaUnited States
-
National Institute of Allergy and Infectious Diseases...CompletedInfluenza Immunisation | Avian InfluenzaUnited States
-
National Institute of Allergy and Infectious Diseases...National Institutes of Health (NIH)CompletedInfluenza AUnited States
-
National Institute of Allergy and Infectious Diseases...CompletedInfluenza | Avian Influenza | H1N1 InfluenzaUnited States
Clinical Trials on Live attenuated influenza vaccine (LAIV4)
-
Changchun BCHT Biotechnology Co.He Bei province Center for Disease control and preventionNot yet recruitingInfluenza PreventionChina
-
Changchun BCHT Biotechnology Co.He Bei province Center for Disease control and preventionRecruitingInfluenza PreventionChina
-
National Center for Occupational Health and Infection...US Department of Veterans AffairsTerminated
-
Changchun BCHT Biotechnology Co.National Institutes for Food and Drug Control, China; Simoon Record Pharma... and other collaboratorsCompleted
-
Imperial College LondonPublic Health EnglandCompletedInfluenza VaccinesUnited Kingdom
-
Imperial College Healthcare NHS TrustCompletedInfluenza | Vaccine Virus SheddingUnited Kingdom
-
PATHCenters for Disease Control and Prevention; Institut de Recherche pour le Developpement and other collaboratorsCompleted
-
PATHJohns Hopkins University; Bill and Melinda Gates Foundation; Centers for Disease... and other collaboratorsCompleted
-
University of RochesterNational Institutes of Health (NIH)Withdrawn2009 H1N1 InfluenzaUnited States
-
University of Colorado, DenverMedImmune LLCCompletedHuman Immunodeficiency Virus (HIV)United States